Stocks
Puma Biotechnology, Inc.PBYI
NASDAQHealthcareBiotechnology$5.90+0.34%
Focused on oncology therapeutics, the company develops and commercializes targeted cancer treatments, with its primary product being neratinib, marketed as Nerlynx for HER2-positive breast cancer. The small-cap biopharmaceutical firm generates revenue from approved therapies while continuing clinica...
Market Cap: $300.2M52W Range: $2.58 – $7.68
Congressional Interest in Puma Biotechnology, Inc. (PBYI)
2 members of Congress have disclosed 7 trades in Puma Biotechnology, Inc. (PBYI), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
7
Unique Politicians
2
Buys
4
Sells
3
Who in Congress Is Trading PBYI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-05-15 | Donna Shalala | sell | $1K – $15K |
| 2019-01-23 | Donna Shalala | buy | $1K – $15K |